TITLE:
Nitrosamine Impurities in Pharmaceutical Drug Substances and Drug Products: Risk Assessment, Analytical Validation, Regulatory Guidance, and Lifecycle Management
AUTHORS:
Sai Krishna Bompelliwar, Ravi Teja Meduri, Naveen Kumar Mallampati, Rasheed Babu Shaik, Abhishek Kumar Mishra, Mohit Chintakindi Bhasker
KEYWORDS:
Nitrosamine Impurities, NDMA, NDEA, NDSRIs, ICH M7(R2), ICH Q2(R2), GC-MS/MS, LC-MS/MS, LC-HRMS, Analytical Validation, Risk Assessment, Mutagenic Impurities, CPCA, Acceptable Intake, Pharmaceutical Quality, Lifecycle Approach
JOURNAL NAME:
American Journal of Analytical Chemistry,
Vol.17 No.8,
August
28,
2026
ABSTRACT: Few quality events in the modern pharmaceutical era have carried the regulatory and patient safety weight of the 2018 valsartan nitrosamine crisis. The discovery of N-Nitrosodimethylamine (NDMA) contamination in valsartan drug substance and the cascade of findings in ranitidine, metformin, losartan, and an expanding range of other drug classes that followed, established nitrosamine impurities as one of the most analytically demanding and regulatorily significant challenges facing the pharmaceutical industry. Several N-nitroso compounds are classified as probable or possible human carcinogens under the International Agency for Research on Cancer (IARC) and are now subject to rigorous regulatory control under the FDA Guidance Revision 2 (September 2024), ICH M7(R2), ICH Q2(R2), the EMA Nitrosamine Guidelines, and the WHO Technical Report. Detecting and quantifying nitrosamines reliably at acceptable intake (AI) limits, which can fall as low as 18 nanograms per day for the most potent compounds, demands a level of analytical sophistication that goes well beyond conventional pharmaceutical quality control practice. This review brings together the full landscape of what a pharmaceutical analytical scientist needs to know to build, validate, and sustain a credible nitrosamine impurity control program. The FDA three-step risk assessment framework risk assessment, confirmatory testing, and implementation of risk-mitigation measures are examined in detail, with worked numerical examples demonstrating how specification limits and required limits of quantitation are derived from AI limits and maximum daily dose data for real drug products. The Carcinogenic Potency Categorization Approach (CPCA) for drug-substance-specific nitrosamines (NDSRIs) is explained through structural examples, showing precisely how the alpha-carbon hydrogen count, activating features, and deactivating features combine to determine a compound’s potency category and its corresponding AI limit. Analytical method validation is covered across all ICH Q2(R2) parameters for GC-MS/MS, LC-MS/MS, and LC-HRMS platforms, with particular attention to the aspects that consistently prove most challenging in practice matrix effects and ion suppression in complex pharmaceutical matrices, isotope-labeled internal standard selection and performance, photostability of NDMA and related volatile nitrosamines, robustness evaluation using Design of Experiments approaches, and carryover control at trace-level concentrations. The ICH Q2(R2) and ICH Q14 lifecycle model encompassing Analytical Target Profile definition, Method Operable Design Region characterization, and Continued Method Performance Verification through statistical process control monitoring is discussed as the framework that transforms nitrosamine method management from a one-time compliance exercise into a continuous quality commitment. Case studies from the valsartan, ranitidine, metformin, and losartan recalls are integrated throughout to ground every technical discussion in the real events that shaped current regulatory expectations. This review serves as a technically rigorous and practically actionable reference for pharmaceutical analytical scientists, quality assurance professionals, and regulatory affairs practitioners engaged in nitrosamine impurity control across drug substance and drug product manufacturing.